Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

The role of telomeres and telomerase in cirrhosis and liver cancer.

Nault JC, Ningarhari M, Rebouissou S, Zucman-Rossi J.

Nat Rev Gastroenterol Hepatol. 2019 Sep;16(9):544-558. doi: 10.1038/s41575-019-0165-3. Epub 2019 Jun 28. Review.

PMID:
31253940
2.

Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma.

Nault JC, Martin Y, Caruso S, Hirsch TZ, Bayard Q, Calderaro J, Charpy C, Copie-Bergman C, Ziol M, Bioulac-Sage P, Couchy G, Blanc JF, Nahon P, Amaddeo G, Ganne-Carrie N, Morcrette G, Chiche L, Duvoux C, Faivre S, Laurent A, Imbeaud S, Rebouissou S, Llovet JM, Seror O, Letouzé E, Zucman-Rossi J.

Hepatology. 2019 Jun 17. doi: 10.1002/hep.30811. [Epub ahead of print]

PMID:
31206197
3.

APC germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures.

Morcrette G, Hirsch TZ, Badour E, Pilet J, Caruso S, Calderaro J, Martin Y, Imbeaud S, Letouzé E, Rebouissou S, Branchereau S, Taque S, Chardot C, Guettier C, Scoazec JY, Fabre M, Brugières L, Zucman-Rossi J.

Oncoimmunology. 2019 Mar 28;8(6):e1583547. doi: 10.1080/2162402X.2019.1583547. eCollection 2019.

4.

Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response.

Caruso S, Calatayud AL, Pilet J, La Bella T, Rekik S, Imbeaud S, Letouzé E, Meunier L, Bayard Q, Rohr-Udilova N, Péneau C, Grasl-Kraupp B, de Koning L, Ouine B, Bioulac-Sage P, Couchy G, Calderaro J, Nault JC, Zucman-Rossi J, Rebouissou S.

Gastroenterology. 2019 Sep;157(3):760-776. doi: 10.1053/j.gastro.2019.05.001. Epub 2019 May 4.

PMID:
31063779
5.

Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations.

Adebayo Michael AO, Ko S, Tao J, Moghe A, Yang H, Xu M, Russell JO, Pradhan-Sundd T, Liu S, Singh S, Poddar M, Monga JS, Liu P, Oertel M, Ranganathan S, Singhi A, Rebouissou S, Zucman-Rossi J, Ribback S, Calvisi D, Qvartskhava N, Görg B, Häussinger D, Chen X, Monga SP.

Cell Metab. 2019 May 7;29(5):1135-1150.e6. doi: 10.1016/j.cmet.2019.01.002. Epub 2019 Jan 31.

PMID:
30713111
6.

Recurrent activating mutations of PPARγ associated with luminal bladder tumors.

Rochel N, Krucker C, Coutos-Thévenot L, Osz J, Zhang R, Guyon E, Zita W, Vanthong S, Hernandez OA, Bourguet M, Badawy KA, Dufour F, Peluso-Iltis C, Heckler-Beji S, Dejaegere A, Kamoun A, de Reyniès A, Neuzillet Y, Rebouissou S, Béraud C, Lang H, Massfelder T, Allory Y, Cianférani S, Stote RH, Radvanyi F, Bernard-Pierrot I.

Nat Commun. 2019 Jan 16;10(1):253. doi: 10.1038/s41467-018-08157-y.

7.

Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma.

Bárcena-Varela M, Caruso S, Llerena S, Álvarez-Sola G, Uriarte I, Latasa MU, Urtasun R, Rebouissou S, Alvarez L, Jimenez M, Santamaría E, Rodriguez-Ortigosa C, Mazza G, Rombouts K, San José-Eneriz E, Rabal O, Agirre X, Iraburu M, Santos-Laso A, Banales JM, Zucman-Rossi J, Prósper F, Oyarzabal J, Berasain C, Ávila MA, Fernández-Barrena MG.

Hepatology. 2019 Feb;69(2):587-603. doi: 10.1002/hep.30168. Epub 2019 Jan 4.

PMID:
30014490
8.

Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas.

Nault JC, Couchy G, Caruso S, Meunier L, Caruana L, Letouzé E, Rebouissou S, Paradis V, Calderaro J, Zucman-Rossi J.

Hepatology. 2018 Sep;68(3):964-976. doi: 10.1002/hep.29884. Epub 2018 Jun 6.

PMID:
29572896
9.

Reply.

Rebouissou S, Bioulac-Sage P, Nault JC, Calderaro J, Zucman-Rossi J.

Hepatology. 2017 Dec;66(6):2093-2094. doi: 10.1002/hep.29563. Epub 2017 Nov 6. No abstract available.

PMID:
28961324
10.

Note of caution: Contaminations of hepatocellular cell lines.

Rebouissou S, Zucman-Rossi J, Moreau R, Qiu Z, Hui L.

J Hepatol. 2017 Nov;67(5):896-897. doi: 10.1016/j.jhep.2017.08.002. Epub 2017 Aug 12. No abstract available.

PMID:
28807831
11.

A phosphokinome-based screen uncovers new drug synergies for cancer driven by liver-specific gain of nononcogenic receptor tyrosine kinases.

Fan Y, Arechederra M, Richelme S, Daian F, Novello C, Calderaro J, Di Tommaso L, Morcrette G, Rebouissou S, Donadon M, Morenghi E, Zucman-Rossi J, Roncalli M, Dono R, Maina F.

Hepatology. 2017 Nov;66(5):1644-1661. doi: 10.1002/hep.29304. Epub 2017 Sep 29.

PMID:
28586114
12.

Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro.

Rebouissou S, La Bella T, Rekik S, Imbeaud S, Calatayud AL, Rohr-Udilova N, Martin Y, Couchy G, Bioulac-Sage P, Grasl-Kraupp B, de Koning L, Ganne-Carrié N, Nault JC, Ziol M, Zucman-Rossi J.

Clin Cancer Res. 2017 Aug 1;23(15):4364-4375. doi: 10.1158/1078-0432.CCR-16-3118. Epub 2017 Feb 28.

13.

Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.

Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, Bacq Y, Calderaro J, Paradis V, Ramos J, Scoazec JY, Gnemmi V, Sturm N, Guettier C, Fabre M, Savier E, Chiche L, Labrune P, Selves J, Wendum D, Pilati C, Laurent A, De Muret A, Le Bail B, Rebouissou S, Imbeaud S; GENTHEP Investigators, Bioulac-Sage P, Letouzé E, Zucman-Rossi J.

Gastroenterology. 2017 Mar;152(4):880-894.e6. doi: 10.1053/j.gastro.2016.11.042. Epub 2016 Dec 7.

14.

Identification of targeted therapy for an aggressive subgroup of muscle-invasive bladder cancers.

Lebret T, Neuzillet Y, Houede N, Rebouissou S, Bernard-Pierrot I, De Reynies A, Benhamou S, Allory Y, Radvanyi F.

Mol Cell Oncol. 2015 Jul 9;2(4):e999507. doi: 10.1080/23723556.2014.999507. eCollection 2015 Oct-Dec.

15.

Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression.

Rebouissou S, Franconi A, Calderaro J, Letouzé E, Imbeaud S, Pilati C, Nault JC, Couchy G, Laurent A, Balabaud C, Bioulac-Sage P, Zucman-Rossi J.

Hepatology. 2016 Dec;64(6):2047-2061. doi: 10.1002/hep.28638. Epub 2016 Jun 11.

PMID:
27177928
16.

L'Epidermal Growth Factor Receptor (EGFR) est une cible thérapeutique pour un sous-groupe de tumeurs de vessie agressives de phénotype de type basal.

Neuzillet Y, Rebouissou S, De Reynies A, Lepage M, Krucker C, Chapeaublanc E, Herault A, Kamoun A, Caillault A, Letouze E, Elarouci N, Decoux Y, Molinie V, Vordos D, Laplanche A, Maille P, Soyeux P, Ofualuka K, Reyal F, Biton A, Sibony M, Paoletti X, Southgate J, Benhamou S, Allory Y, Radvanyi F, Lebret T.

Prog Urol. 2014 Nov;24(13):806. doi: 10.1016/j.purol.2014.08.053. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461580
17.

A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis.

Remy E, Rebouissou S, Chaouiya C, Zinovyev A, Radvanyi F, Calzone L.

Cancer Res. 2015 Oct 1;75(19):4042-52. doi: 10.1158/0008-5472.CAN-15-0602. Epub 2015 Aug 3. Erratum in: Cancer Res. 2016 Jan 15;76(2):505.

18.

NRF2/KEAP1 and Wnt/β-catenin in the multistep process of liver carcinogenesis in humans and rats.

Nault JC, Rebouissou S, Zucman Rossi J.

Hepatology. 2015 Sep;62(3):677-9. doi: 10.1002/hep.27828. Epub 2015 Jun 9. No abstract available.

PMID:
25846427
19.

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.

Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage P, Stratton MR, Llovet JM, Zucman-Rossi J.

Nat Genet. 2015 May;47(5):505-511. doi: 10.1038/ng.3252. Epub 2015 Mar 30.

20.

Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes.

Biton A, Bernard-Pierrot I, Lou Y, Krucker C, Chapeaublanc E, Rubio-Pérez C, López-Bigas N, Kamoun A, Neuzillet Y, Gestraud P, Grieco L, Rebouissou S, de Reyniès A, Benhamou S, Lebret T, Southgate J, Barillot E, Allory Y, Zinovyev A, Radvanyi F.

Cell Rep. 2014 Nov 20;9(4):1235-45. doi: 10.1016/j.celrep.2014.10.035. Epub 2014 Nov 13.

21.

EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.

Rebouissou S, Bernard-Pierrot I, de Reyniès A, Lepage ML, Krucker C, Chapeaublanc E, Hérault A, Kamoun A, Caillault A, Letouzé E, Elarouci N, Neuzillet Y, Denoux Y, Molinié V, Vordos D, Laplanche A, Maillé P, Soyeux P, Ofualuka K, Reyal F, Biton A, Sibony M, Paoletti X, Southgate J, Benhamou S, Lebret T, Allory Y, Radvanyi F.

Sci Transl Med. 2014 Jul 9;6(244):244ra91. doi: 10.1126/scitranslmed.3008970.

22.

PI3K/AKT pathway activation in bladder carcinogenesis.

Calderaro J, Rebouissou S, de Koning L, Masmoudi A, Hérault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y.

Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24.

23.

A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection.

Nault JC, De Reyniès A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, Decaens T, Franco D, Imbeaud S, Rousseau F, Azoulay D, Saric J, Blanc JF, Balabaud C, Bioulac-Sage P, Laurent A, Laurent-Puig P, Llovet JM, Zucman-Rossi J.

Gastroenterology. 2013 Jul;145(1):176-187. doi: 10.1053/j.gastro.2013.03.051. Epub 2013 Apr 6.

PMID:
23567350
24.

Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I.

Calderaro J, Labrune P, Morcrette G, Rebouissou S, Franco D, Prévot S, Quaglia A, Bedossa P, Libbrecht L, Terracciano L, Smit GP, Bioulac-Sage P, Zucman-Rossi J.

J Hepatol. 2013 Feb;58(2):350-7. doi: 10.1016/j.jhep.2012.09.030. Epub 2012 Oct 6.

PMID:
23046672
25.

CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.

Rebouissou S, Hérault A, Letouzé E, Neuzillet Y, Laplanche A, Ofualuka K, Maillé P, Leroy K, Riou A, Lepage ML, Vordos D, de la Taille A, Denoux Y, Sibony M, Guyon F, Lebret T, Benhamou S, Allory Y, Radvanyi F.

J Pathol. 2012 Jul;227(3):315-24. doi: 10.1002/path.4017. Epub 2012 May 8.

PMID:
22422578
26.

HNF1α inhibition triggers epithelial-mesenchymal transition in human liver cancer cell lines.

Pelletier L, Rebouissou S, Vignjevic D, Bioulac-Sage P, Zucman-Rossi J.

BMC Cancer. 2011 Oct 5;11:427. doi: 10.1186/1471-2407-11-427.

27.

Loss of hepatocyte nuclear factor 1alpha function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis.

Pelletier L, Rebouissou S, Paris A, Rathahao-Paris E, Perdu E, Bioulac-Sage P, Imbeaud S, Zucman-Rossi J.

Hepatology. 2010 Feb;51(2):557-66. doi: 10.1002/hep.23362.

PMID:
20041408
28.

[Gp130-activating mutations in inflammatory liver adenomas].

Zucman-Rossi J, Amessou M, Bioulac-Sage P, Rebouissou S.

Med Sci (Paris). 2008 Dec;24(12):1113-4. doi: 10.1051/medsci/200824121113. French. No abstract available.

29.

Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.

Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C, Izard T, Balabaud C, Bioulac-Sage P, Zucman-Rossi J.

Nature. 2009 Jan 8;457(7226):200-4. doi: 10.1038/nature07475. Epub 2008 Nov 19.

30.

The beta-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules.

Rebouissou S, Couchy G, Libbrecht L, Balabaud C, Imbeaud S, Auffray C, Roskams T, Bioulac-Sage P, Zucman-Rossi J.

J Hepatol. 2008 Jul;49(1):61-71. doi: 10.1016/j.jhep.2008.03.013. Epub 2008 Apr 18.

31.

MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations.

Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J.

Hepatology. 2008 Jun;47(6):1955-63. doi: 10.1002/hep.22256.

32.

Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma.

Rebouissou S, Bioulac-Sage P, Zucman-Rossi J.

J Hepatol. 2008 Jan;48(1):163-70. Epub 2007 Oct 30. Review.

PMID:
17997499
33.

Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry.

Bioulac-Sage P, Rebouissou S, Thomas C, Blanc JF, Saric J, Sa Cunha A, Rullier A, Cubel G, Couchy G, Imbeaud S, Balabaud C, Zucman-Rossi J.

Hepatology. 2007 Sep;46(3):740-8.

PMID:
17663417
34.

Genotype phenotype classification of hepatocellular adenoma.

Bioulac-Sage P, Blanc JF, Rebouissou S, Balabaud C, Zucman-Rossi J.

World J Gastroenterol. 2007 May 21;13(19):2649-54. Review.

35.

HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation.

Rebouissou S, Imbeaud S, Balabaud C, Boulanger V, Bertrand-Michel J, Tercé F, Auffray C, Bioulac-Sage P, Zucman-Rossi J.

J Biol Chem. 2007 May 11;282(19):14437-46. Epub 2007 Mar 22.

36.

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.

Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, Hérault A, Saric J, Belghiti J, Franco D, Bioulac-Sage P, Laurent-Puig P, Zucman-Rossi J.

Hepatology. 2007 Jan;45(1):42-52.

PMID:
17187432
37.

Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC.

Zucman-Rossi J, Jeannot E, Nhieu JT, Scoazec JY, Guettier C, Rebouissou S, Bacq Y, Leteurtre E, Paradis V, Michalak S, Wendum D, Chiche L, Fabre M, Mellottee L, Laurent C, Partensky C, Castaing D, Zafrani ES, Laurent-Puig P, Balabaud C, Bioulac-Sage P.

Hepatology. 2006 Mar;43(3):515-24.

PMID:
16496320
38.

Childhood leukaemia, polymorphisms of metabolism enzyme genes, and interactions with maternal tobacco, coffee and alcohol consumption during pregnancy.

Clavel J, Bellec S, Rebouissou S, Ménégaux F, Feunteun J, Bonaïti-Pellié C, Baruchel A, Kebaili K, Lambilliotte A, Leverger G, Sommelet D, Lescoeur B, Beaune P, Hémon D, Loriot MA.

Eur J Cancer Prev. 2005 Dec;14(6):531-40.

PMID:
16284498
39.

Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver.

Bioulac-Sage P, Rebouissou S, Sa Cunha A, Jeannot E, Lepreux S, Blanc JF, Blanché H, Le Bail B, Saric J, Laurent-Puig P, Balabaud C, Zucman-Rossi J.

Gastroenterology. 2005 May;128(5):1211-8.

PMID:
15887105
40.
41.

Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas.

Rebouissou S, Vasiliu V, Thomas C, Bellanné-Chantelot C, Bui H, Chrétien Y, Timsit J, Rosty C, Laurent-Puig P, Chauveau D, Zucman-Rossi J.

Hum Mol Genet. 2005 Mar 1;14(5):603-14. Epub 2005 Jan 13.

PMID:
15649945
42.

Mutation of TCF1 encoding hepatocyte nuclear factor 1alpha in gynecological cancer.

Rebouissou S, Rosty C, Lecuru F, Boisselier S, Bui H, Le Frere-Belfa MA, Sastre X, Laurent-Puig P, Zucman-Rossi J.

Oncogene. 2004 Sep 30;23(45):7588-92.

PMID:
15326484
43.

Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas.

Cazals-Hatem D, Rebouissou S, Bioulac-Sage P, Bluteau O, Blanché H, Franco D, Monges G, Belghiti J, Sa Cunha A, Laurent-Puig P, Degott C, Zucman-Rossi J.

J Hepatol. 2004 Aug;41(2):292-8.

PMID:
15288479

Supplemental Content

Loading ...
Support Center